The Impact of Immune Response on HTLV-I in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)

Document Type: Review Article

Authors

1 Inflammation and Inflammatory Diseases Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran

2 Allergy Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

 
 
Human T lymphotropic virus type I (HTLV-I) is a retrovirus which is associated with adult T cells leukaemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in a minority of HTLV-I-infected individuals. It is not clear why a minority of HTLV-I-infected individuals develop HAM/TSP and majority remains lifelong carriers. It seems that the interaction between the virus and the immune response plays an important role in HTLV-I-associated diseases. Although the role of the immune response in HTLV-I pathogenesis is not fully understood, however it seems that the efficacy of the immune response which is involved in controlling or limiting of viral persistence determines the outcome of HTLV-I-associated diseases. Here we discuss the role of innate and adaptive immune response and also the risk factors contribute to the observed differences between HAM/TSP patients and asymptomatic HTLV-I carriers.
 

Keywords


Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD,Gallo RC.

Detection and isolation of type C retrovirus particles from fresh

and cultured lymphocytes of a patient with cutaneous T-cell

lymphoma. Proc Natl Acad Sci U S A 1980; 77:7415-7419.

2. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A

 

, et al.

 

Antibodies to human T-lymphotropic virus type-I in patients

with tropical spastic paraparesis. Lancet 1985; 2:407-410.

3. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita

KI

, et al.

Adult T-cell leukemia: antigen in an ATL cell line and

detection of antibodies to the antigen in human sera. Proc Natl

 

Acad Sci U S A 1981; 78:6476-6480.

 

4. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC,Murphy EL.

 

Global epidemiology of HTLV-I infection and associated diseases.

 

Oncogene 2005; 24:6058-6068.

 

5. de The G,Bomford R. An HTLV-I vaccine: why, how, for whom?

 

AIDS Res Hum Retroviruses 1993; 9:381-386.

 

6. Hlela C, Shepperd S, Khumalo NP,Taylor GP. The prevalence of human

 

T-cell lymphotropic virus type 1 in the general population is

 

unknown. AIDS Rev 2009; 11:205-214.

 

7. Morofuji-Hirata M, Kajiyama W, Nakashima K, Noguchi A, Hayashi

 

J,Kashiwagi S. Prevalence of antibody to human T-cell lymphotropic

 

virus type I in Okinawa, Japan, after an interval of 9 years.

 

Am J Epidemiol 1993; 137:43-48.

 

8. Hinuma Y, Komoda H, Chosa T, Kondo T, Kohakura M, Takenaka

 

T

 

 

, et al.

Antibodies to adult T-cell leukemia-virus-associated antigen

(ATLA) in sera from patients with ATL and controls in Japan:

 

a nation-wide sero-epidemiologic study. Int J Cancer 1982; 29:631-

 

635.

 

9. Blattner WA, Kalyanaraman VS, Robert-Guroff M, Lister TA, Galton

 

DA, Sarin PS

 

 

, et al.

The human type-C retrovirus, HTLV, in

Blacks from the Caribbean region, and relationship to adult Tcell

 

leukemia/lymphoma. Int J Cancer 1982; 30:257-264.

 

10. Reeves WC, Saxinger C, Brenes MM, Quiroz E, Clark JW, Hoh MW

 

 

 

,

et al.

 

 

 

Human T-cell lymphotropic virus type I (HTLV-I) seroepidemiology

and risk factors in metropolitan Panama. Am J Epidemiol

 

1988; 127:532-539.

 

11. Maloney EM, Ramirez H, Levin A,Blattner WA. A survey of the human

 

T-cell lymphotropic virus type I (HTLV-I) in south-western

 

Colombia. Int J Cancer 1989; 44:419-423.

 

12. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F,

 

Bidkhori HR, Shamsian SK, Ahmadi S

 

 

, et al.

High prevalence of

HTLV-I infection in Mashhad, Northeast Iran: a population-based

 

seroepidemiology survey. J Clin Virol 2011; 52:172-176.

 

13. Azarpazhooh MR, Hasanpour K, Ghanbari M, Rezaee SA, Mashkani

 

B, Hedayati-Moghaddam MR

 

 

, et al.

Human T-Lymphotropic

Virus Type 1 Prevalence in Northeastern Iran, Sabzevar: An Epidemiologic-

 

Based Study and Phylogenetic Analysis. AIDS Res Hum

 

Retroviruses 2012;

 

14. Tarhini M, Kchour G, Zanjani DS, Rafatpanah H, Otrock ZK, Bazarbachi

 

A

 

 

, et al.

Declining tendency of human T-cell leukaemia

virus type I carrier rates among blood donors in Mashhad, Iran.

 

Pathology 2009; 41:498-499.

 

15. Rafatpanah H, Farid R, Golanbar G,Jabbari Azad F. HTLV-I Infection:

 

virus structure, immune response to the virus and genetic

 

association studies in HTLV-I-infected individuals. Iran J Allergy

 

Asthma Immunol 2006; 5:153-166.

 

16. Bangham CR,Osame M. Cellular immune response to HTLV-I. Oncogene

 

2005; 24:6035-6046.

 

17. Furukawa Y, Yamashita M, Usuku K, Izumo S, Nakagawa M,Osame

 

M. Phylogenetic subgroups of human T cell lymphotropic virus

 

(HTLV) type I in the tax gene and their association with different

 

risks for HTLV-I-associated myelopathy/tropical spastic paraparesis.

 

J Infect Dis 2000; 182:1343-1349.

 

18. Daenke S, Nightingale S, Cruickshank JK,Bangham CR. Sequence

 

variants of human T-cell lymphotropic virus type I from patients

 

with tropical spastic paraparesis and adult T-cell leukemia do

 

not distinguish neurological from leukemic isolates. J Virol

 

1990; 64:1278-1282.

 

 

207

Immunopathogenecity of HTLV-I in HAM/TSP Rafatpanah H et al

Iran J Basic Med Sci; Vol. 16, No. 3, Mar 2013

19. Mahieux R, de The G,Gessain A. The tax mutation at nucleotide

7959 of human T-cell leukemia virus type 1 (HTLV-I) is not associated

with tropical spastic paraparesis/HTLV-I-associated myelopathy

but is linked to the cosmopolitan molecular genotype.

J Virol 1995; 69:5925-5927.

20. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P,Dalgleish

AG.

In vivo

cellular tropism of human T-cell leukemia virus type 1.

J Virol 1990; 64:5682-5687.

 

21. Koyanagi Y, Itoyama Y, Nakamura N, Takamatsu K, Kira J, Iwamasa

 

T

 

 

, et al. In vivo

infection of human T-cell leukemia virus type I in

non-T cells. Virology 1993; 196:25-33.

 

22. Hanon E, Stinchcombe JC, Saito M, Asquith BE, Taylor GP, Tanaka

 

Y

 

 

, et al.

Fratricide among CD8(+) T lymphocytes naturally infected

with human T cell lymphotropic virus type I. Immunity 2000;

 

13:657-664.

 

23. Cho I, Sugimoto M, Mita S, Tokunaga M, Imamura F,Ando M.

 

 

 

In

vivo

 

 

 

proviral burden and viral RNA expression in T cell subsets of

patients with human T lymphotropic virus type-1-associated myelopathy/

 

tropical spastic paraparesis. Am J Trop Med Hyg 1995;

 

53:412-418.

 

24. Koralnik IJ, Lemp JF, Jr., Gallo RC,Franchini G.

 

 

In vitro

infection of

human macrophages by human T-cell leukemia/lymphotropic

 

virus type I (HTLV-I). AIDS Res Hum Retroviruses 1992; 8:1845-

 

1849.

 

25. de Revel T, Mabondzo A, Gras G, Delord B, Roques P, Boussin F

 

 

 

, et

al. In vitro

 

 

 

infection of human macrophages with human T-cell

leukemia virus type 1. Blood 1993; 81:1598-1606.

 

26. Macatonia SE, Cruickshank JK, Rudge P,Knight SC. Dendritic cells

 

from patients with tropical spastic paraparesis are infected with

 

HTLV-I and stimulate autologous lymphocyte proliferation. AIDS

 

Res Hum Retroviruses 1992; 8:1699-1706.

 

27. Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N,Uchiyama

 

T. Depletion and impaired interferon-alpha-producing capacity

 

of blood plasmacytoid dendritic cells in human T-cell leukaemia

 

virus type I-infected individuals. Br J Haematol 2004; 125:568-575.

 

28. Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC,Ruscetti

 

FW. Cell-free HTLV-I infects dendritic cells leading to transmission

 

and transformation of CD4(+) T cells. Nat Med 2008; 14:429-

 

436.

 

29. Journo C,Mahieux R. HTLV-I and innate immunity. Viruses 2011;

 

3:1374-1394.

 

30. Jain P, Manuel SL, Khan ZK, Ahuja J, Quann K,Wigdahl B. DCSIGN

 

mediates cell-free infection and transmission of human

 

T-cell lymphotropic virus type 1 by dendritic cells. J Virol 2009;

 

83:10908-10921.

 

31. Oliere S, Douville R, Sze A, Belgnaoui SM,Hiscott J. Modulation of

 

innate immune responses during human T-cell leukemia virus

 

(HTLV-I) pathogenesis. Cytokine Growth Factor Rev 2011; 22:197-

 

210.

 

32. Vivier E, Tomasello E, Baratin M, Walzer T,Ugolini S. Functions of

 

natural killer cells. Nat Immunol 2008; 9:503-510.

 

33. Fujihara K, Itoyama Y, Yu F, Kubo C,Goto I. Cellular immune surveillance

 

against HTLV-I infected T lymphocytes in HTLV-I associated

 

myelopathy/tropical spastic paraparesis (HAM/TSP). J Neurol

 

Sci 1991; 105:99-107.

 

34. Yu F, Itoyama Y, Fujihara K,Goto I. Natural killer (NK) cells in

 

HTLV-I-associated myelopathy/tropical spastic paraparesis-decrease

 

in NK cell subset populations and activity in HTLV-I seropositive

 

individuals. J Neuroimmunol 1991; 33:121-128.

 

35. Saito M, Braud VM, Goon P, Hanon E, Taylor GP, Saito A

 

 

, et al.

Low

frequency of CD94/NKG2A+ T lymphocytes in patients with

 

HTLV-I-associated myelopathy/tropical spastic paraparesis, but

 

not in asymptomatic carriers. Blood 2003; 102:577-584.

 

36. Vine AM, Heaps AG, Kaftantzi L, Mosley A, Asquith B, Witkover A

 

 

 

,

et al.

 

 

 

The role of CTLs in persistent viral infection: cytolytic gene

expression in CD8+ lymphocytes distinguishes between individuals

 

with a high or low proviral load of human T cell lymphotropic

 

virus type 1. J Immunol 2004; 173:5121-5129.

 

37. Norris PJ, Hirschkorn DF, DeVita DA, Lee TH,Murphy EL. Human T

 

cell leukemia virus type 1 infection drives spontaneous proliferation

 

of natural killer cells. Virulence 2010; 1:19-28.

 

38. Azakami K, Sato T, Araya N, Utsunomiya A, Kubota R, Suzuki K

 

 

 

,

et al.

 

 

 

Severe loss of invariant NKT cells exhibiting anti-HTLV-I activity

in patients with HTLV-I-associated disorders. Blood 2009;

 

114:3208-3215.

 

39. Ndhlovu LC, Snyder-Cappione JE, Carvalho KI, Leal FE, Loo CP,

 

Bruno FR

 

 

, et al.

Lower numbers of circulating Natural Killer T (NK

T) cells in individuals with human T lymphotropic virus type 1

 

(HTLV-I) associated neurological disease. Clin Exp Immunol

 

2009; 158:294-299.

 

40. Manns A, Hisada M,La Grenade L. Human T-lymphotropic virus

 

type I infection. Lancet 1999; 353:1951-1958.

 

41. Bangham CR. The immune response to HTLV-I. Curr Opin Immunol

 

2000; 12:397-402.

 

42. Manns A, Murphy EL, Wilks R, Haynes G, Figueroa JP, Hanchard

 

B

 

 

, et al.

Detection of early human T-cell lymphotropic virus type

I antibody patterns during seroconversion among transfusion

 

recipients. Blood 1991; 77:896-905.

 

43. Nagasato K, Nakamura T, Shirabe S, Shibayama K, Ohishi K, Ichinose

 

K

 

 

, et al.

Presence of serum anti-human T-lymphotropic virus

type I (HTLV-I) IgM antibodies means persistent active replication

 

of HTLV-I in HTLV-I-associated myelopathy. J Neurol Sci 1991;

 

103:203-208.

 

44. Kira J, Nakamura M, Sawada T, Koyanagi Y, Ohori N, Itoyama Y

 

 

 

, et

al.

 

 

 

Antibody titers to HTLV-I-p40tax protein and gag-env hybrid

protein in HTLV-I-associated myelopathy/tropical spastic paraparesis:

 

correlation with increased HTLV-I proviral DNA load. J

 

Neurol Sci 1992; 107:98-104.

 

45. Grimaldi LM, Roos RP, Devare SG, Casey JM, Maruo Y, Hamada T

 

 

 

,

et al.

 

 

 

HTLV-I-associated myelopathy: oligoclonal immunoglobulin

G bands contain anti-HTLV-I p24 antibody. Ann Neurol 1988;

 

24:727-731.

 

46. Yoshida M, Osame M, Kawai H, Toita M, Kuwasaki N, Nishida Y

 

 

 

, et

al.

 

 

 

Increased replication of HTLV-I in HTLV-I-associated myelopathy.

Ann Neurol 1989; 26:331-335.

 

47. Kira J, Koyanagi Y, Yamada T, Itoyama Y, Goto I, Yamamoto N

 

 

 

, et al.

 

Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy:

a quantitative polymerase chain reaction study. Ann Neurol 1991;

29:194-201.

48. Gessain A, Saal F, Gout O, Daniel MT, Flandrin G, de The G

 

, et al.

 

High human T-cell lymphotropic virus type I proviral DNA load

with polyclonal integration in peripheral blood mononuclear

cells of French West Indian, Guianese, and African patients with

tropical spastic paraparesis. Blood 1990; 75:428-433.

49. Kubota R, Fujiyoshi T, Izumo S, Yashiki S, Maruyama I, Osame

M

, et al.

Fluctuation of HTLV-I proviral DNA in peripheral blood

mononuclear cells of HTLV-I-associated myelopathy. J Neuroimmunol

 

1993; 42:147-154.

 

50. Kirk PD, Witkover A, Courtney A, Lewin AM, Wait R, Stumpf MP

 

 

 

,

et al.

 

 

 

Plasma proteome analysis in HTLV-I-associated myelopathy/

tropical spastic paraparesis. Retrovirology 2011; 8:81.

 

51. Abbas AK, Lichtman AH,Pober JS. Effector mechanisms of T cellmediated

 

immune reactions. In: Abbas AK, Lichtman AH and

 

Pober JS, editors. Cellular and Molecular Immunology. 3rd ed.

 

Philadelphia, PA: Saunders; 1997. p. 278-296.

 

52. Jacobson S, Shida H, McFarlin DE, Fauci AS,Koenig S. Circulating

 

CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients

 

with HTLV-I associated neurological disease. Nature 1990;

 

348:245-248.

 

53. Jacobson S, Reuben JS, Streilein RD,Palker TJ. Induction of CD4+,

 

human T lymphotropic virus type-1-specific cytotoxic T lymphocytes

 

from patients with HAM/TSP. Recognition of an immunogenic

 

region of the gp46 envelope glycoprotein of human T lymphotropic

 

virus type-1. J Immunol 1991; 146:1155-1162.

 

54. Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T,Jacobson S.

 

High human T cell lymphotropic virus type 1 (HTLV-I)-specific

 

precursor cytotoxic T lymphocyte frequencies in patients with

 

HTLV-I-associated neurological disease. J Exp Med 1993; 177:1567-

 

1573.

 

55. Parker CE, Daenke S, Nightingale S,Bangham CR. Activated, HTLVI-

 

specific cytotoxic T-lymphocytes are found in healthy seropositives

 

as well as in patients with tropical spastic paraparesis. Vi

 

 

 

208

 

Rafatpanah H et al Immunopathogenecity of HTLV-I in HAM/TSP

Iran J Basic Med Sci; Vol. 16, No. 3, Mar 2013

rology 1992; 188:628-636.

56. Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima

G

, et al.

Predominant recognition of human T cell leukemia

virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic

 

T cells directed against HTLV-I-infected cells. Int Immunol 1991;

 

3:761-767.

 

57. Daenke S, Kermode AG, Hall SE, Taylor G, Weber J, Nightingale

 

S

 

 

, et al.

High activated and memory cytotoxic T-cell responses

to HTLV-I in healthy carriers and patients with tropical spastic

 

paraparesis. Virology 1996; 217:139-146.

 

58. Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP

 

 

 

, et

al.

 

 

 

Direct visualization of antigen-specific T cells: HTLV-I Tax11-

19- specific CD8(+) T cells are activated in peripheral blood and

 

accumulate in cerebrospinal fluid from HAM/TSP patients. Proc

 

Natl Acad Sci U S A 1998; 95:7568-7573.

 

59. Bieganowska K, Hollsberg P, Buckle GJ, Lim DG, Greten TF, Schneck

 

J

 

 

, et al.

Direct analysis of viral-specific CD8+ T cells with soluble

HLA-A2/Tax11-19 tetramer complexes in patients with human

 

T cell lymphotropic virus-associated myelopathy. J Immunol

 

1999; 162:1765-1771.

 

60. Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP,Jacobson S. Increased

 

activated human T cell lymphotropic virus type I (HTLVI)

 

Tax11-19-specific memory and effector CD8+ cells in patients

 

with HTLV-I-associated myelopathy/tropical spastic paraparesis:

 

correlation with HTLV-I provirus load. J Infect Dis 2001; 183:197-

 

205.

 

61. Biddison WE, Kubota R, Kawanishi T, Taub DD, Cruikshank WW,

 

Centre DM

 

 

, et al.

Human T cell leukemia virus type I (HTLV-I)-specific

CD8+ CTL clones from patients with HTLV-I-associated neurologic

 

disease secrete proinflammatory cytokines, chemokines,

 

and matrix metalloproteinase. J Immunol 1997; 159:2018-2025.

 

62. Kubota R, Kawanishi T, Matsubara H, Manns A,Jacobson S. Demonstration

 

of human T lymphotropic virus type I (HTLV-I) taxspecific

 

CD8+ lymphocytes directly in peripheral blood of HTLVI-

 

associated myelopathy/tropical spastic paraparesis patients by

 

intracellular cytokine detection. J Immunol 1998; 161:482-488.

 

63. Kubota R, Kawanishi T, Matsubara H, Manns A,Jacobson S. HTLV-I

 

specific IFN-gamma+ CD8+ lymphocytes correlate with the proviral

 

load in peripheral blood of infected individuals. J Neuroimmunol

 

2000; 102:208-215.

 

64. Saito M. Immunogenetics and the Pathological Mechanisms

 

of Human T-Cell Leukemia VirusType 1- (HTLV-I-)Associated Myelopathy/

 

Tropical Spastic Paraparesis (HAM/TSP). Interdiscip Perspect

 

Infect Dis 2010; 2010:478461.

 

65. Goon PK, Hanon E, Igakura T, Tanaka Y, Weber JN, Taylor GP

 

 

 

, et al.

 

High frequencies of Th1-type CD4(+) T cells specific to HTLV-I Env

and Tax proteins in patients with HTLV-I-associated myelopathy/

tropical spastic paraparesis. Blood 2002; 99:3335-3341.

66. Kitze B, Usuku K, Yamano Y, Yashiki S, Nakamura M, Fujiyoshi T

 

,

et al.

 

 

 

Human CD4+ T lymphocytes recognize a highly conserved

epitope of human T lymphotropic virus type 1 (HTLV-I) env gp21

 

restricted by HLA DRB1*0101. Clin Exp Immunol 1998; 111:278-285.

 

67. Goon PK, Igakura T, Hanon E, Mosley AJ, Barfield A, Barnard AL

 

 

 

, et

al.

 

 

 

Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+

T cells: immunodominance hierarchy and preferential infection

 

with HTLV-I. J Immunol 2004; 172:1735-1743.

 

68. Bangham CR. The immune control and cell-to-cell spread of human

 

T-lymphotropic virus type 1. J Gen Virol 2003; 84:3177-3189.

 

69. Goon PK, Igakura T, Hanon E, Mosley AJ, Asquith B, Gould KG

 

 

 

, et

al.

 

 

 

High circulating frequencies of tumor necrosis factor alphaand

interleukin-2-secreting human T-lymphotropic virus type 1

 

(HTLV-I)-specific CD4+ T cells in patients with HTLV-I-associated

 

neurological disease. J Virol 2003; 77:9716-9722.

 

70. Sabouri AH, Saito M, Usuku K, Bajestan SN, Mahmoudi M, Forughipour

 

M

 

 

, et al.

Differences in viral and host genetic risk factors for

development of human T-cell lymphotropic virus type 1 (HTLV-I)-

 

associated myelopathy/tropical spastic paraparesis between Iranian

 

and Japanese HTLV-I-infected individuals. J Gen Virol 2005;

 

86:773-781.

 

71. Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD

 

 

 

,

et al.

 

 

 

The influence of HLA class I alleles and heterozygosity on

the outcome of human T cell lymphotropic virus type I infection.

 

J Immunol 2000; 165:7278-7284.

 

72. Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J

 

 

 

, et

al.

 

 

 

HLA alleles determine human T-lymphotropic virus-I (HTLV-I)

proviral load and the risk of HTLV-I-associated myelopathy. Proc

 

Natl Acad Sci U S A 1999; 96:3848-3853.

 

73. Rafatpanah H, Pravica V, Faridhosseini R, Tabatabaei A, Ollier

 

W, Poulton K

 

 

, et al.

Association between HLA-DRB1*01 and HLACw*

08 and outcome following HTLV-I infection. Iran J Immunol

 

2007; 4:94-100.

 

74. Tendler CL, Greenberg SJ, Burton JD, Danielpour D, Kim SJ,

 

Blattner WA

 

 

, et al.

Cytokine induction in HTLV-I associated myelopathy

and adult T-cell leukemia: alternate molecular mechanisms

 

underlying retroviral pathogenesis. J Cell Biochem 1991;

 

46:302-311.

 

75. Hanon E, Goon P, Taylor GP, Hasegawa H, Tanaka Y, Weber JN

 

 

 

, et

al.

 

 

 

High production of interferon gamma but not interleukin-2

by human T-lymphotropic virus type I-infected peripheral blood

 

mononuclear cells. Blood 2001; 98:721-726.

 

76. Fontenot JD, Gavin MA,Rudensky AY. Foxp3 programs the development

 

and function of CD4+CD25+ regulatory T cells. Nat Immunol

 

2003; 4:330-336.

 

77. Hori S, Nomura T,Sakaguchi S. Control of regulatory T cell development

 

by the transcription factor Foxp3. Science 2003;

 

299:1057-1061.

 

78. Yamano Y, Takenouchi N, Li HC, Tomaru U, Yao K, Grant CW

 

 

 

, et al.

 

Virus-induced dysfunction of CD4+CD25+ T cells in patients with

HTLV-I-associated neuroimmunological disease. J Clin Invest

2005; 115:1361-1368.

79. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z

 

, et al.

 

Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant selftolerance

and autoimmune disease. Immunol Rev 2006; 212:8-27.

80. Oh U, Grant C, Griffith C, Fugo K, Takenouchi N,Jacobson S. Reduced

Foxp3 protein expression is associated with inflammatory

disease during human t lymphotropic virus type 1 Infection. J Infect

Dis 2006; 193:1557-1566.

81. Hayashi D, Kubota R, Takenouchi N, Tanaka Y, Hirano R, Takashima

H

, et al.

Reduced Foxp3 expression with increased cytomegalovirus-

specific CTL in HTLV-I-associated myelopathy. J Neuroimmunol

 

2008; 200:115-124.

 

82. Toulza F, Heaps A, Tanaka Y, Taylor GP,Bangham CR. High frequency

 

of CD4+FoxP3+ cells in HTLV-I infection: inverse correlation

 

with HTLV-I-specific CTL response. Blood 2008; 111:5047-5053.

 

83. Best I, Lopez G, Verdonck K, Gonzalez E, Tipismana M, Gotuzzo

 

E

 

 

, et al.

IFN-gamma production in response to Tax 161-233, and

frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate

 

HAM/TSP patients from asymptomatic HTLV-I-carriers

 

in a Peruvian population. Immunology 2009; 128:e777-786.

 

84. Araya N, Sato T, Yagishita N, Ando H, Utsunomiya A, Jacobson S

 

 

 

,

et al.

 

 

 

Human T-lymphotropic virus type 1 (HTLV-I) and regulatory

T cells in HTLV-I-associated neuroinflammatory disease. Viruses

 

2011; 3:1532-1548.

 

85. Ramirez JM, Brembilla NC, Sorg O, Chicheportiche R, Matthes T,

 

Dayer JM

 

 

, et al.

Activation of the aryl hydrocarbon receptor reveals

distinct requirements for IL-22 and IL-17 production by human

 

T helper cells. Eur J Immunol 2010; 40:2450-2459.

 

86. Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D

 

 

 

, et

al.

 

 

 

Frequent expression of CCR4 in adult T-cell leukemia and human

T-cell leukemia virus type 1-transformed T cells. Blood 2002;

 

99:1505-1511.

 

87. Yamano Y, Araya N, Sato T, Utsunomiya A, Azakami K, Hasegawa

 

D

 

 

, et al.

Abnormally high levels of virus-infected IFN-gamma+

CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory

 

disorder. PLoS One 2009; 4:e6517.

 

88. Yoshie O. Expression of CCR4 in adult T-cell leukemia. Leuk Lymphoma

 

2005; 46:185-190.